Pamisel and Pentomics Collaborate on AI Prediction Model for Stem Cell Therapy

[Asia Economy Reporter Hyungsoo Park] Pamicell announced on the 17th that it has signed a business agreement with Pantomics, a medical imaging artificial intelligence software development company, for joint research on biomarkers and AI prediction models.

According to the agreement, they will collaborate to discover imaging biomarkers related to the therapeutic effects and prognosis of stem cell therapies. Based on these biomarkers, they will develop prognosis prediction models.

The specific details include ▲ discovering imaging biomarkers for predicting therapeutic effects and prognosis of stem cells ▲ developing prediction models for stem cell therapeutic effects ▲ research related to image analysis ▲ education and training of research personnel.

Pantomics is a specialized company developing AI software for automatic analysis and diagnosis of medical images. Moving away from traditional qualitative diagnostic methods, it is developing quantitative diagnostic methods using AI and big data. In December last year, it received sales approval for three types of automatic cardiac magnetic resonance imaging (MRI) analysis software from the US FDA and the Korean Ministry of Food and Drug Safety.

A Pamicell official stated, "We plan to discover biomarkers that predict the therapeutic effects of acute myocardial infarction patients based on data obtained from clinical trials," and added, "We hope that this research will enhance the therapeutic efficiency of stem cell therapies."

This content was produced with the assistance of AI translation services.